Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA "Not Happy" Without NDI Guidance, Works To Improve Acceptance Rates

This article was originally published in The Tan Sheet

Executive Summary

FDA is working to raise the acceptance rate for new dietary ingredient notifications from the current level of roughly 25 percent even as much-needed industry guidance is delayed, a Center for Food Safety and Applied Nutrition executive says

You may also be interested in...



McCain-Dorgan NDI Guidance, Steroid Provisions In Senate Food Safety Bill

Requirements that benefit dietary supplement manufacturing and that gained Sen. John McCain's support after he initially proposed legislation considered a threat to the industry are part of the food safety reform bill pending in the Senate.

McCain-Dorgan NDI Guidance, Steroid Provisions In Senate Food Safety Bill

Requirements that benefit dietary supplement manufacturing and that gained Sen. John McCain's support after he initially proposed legislation considered a threat to the industry are part of the food safety reform bill pending in the Senate.

McCain-Dorgan NDI Guidance, Steroid Provisions In Senate Food Safety Bill

Requirements that benefit dietary supplement manufacturing and that gained Sen. John McCain's support after he initially proposed legislation considered a threat to the industry are part of the food safety reform bill pending in the Senate.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel